Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 6, 2012, Pages 384-391

  Zhang, Qing ^a   Liu, Xiujun ^b   Xu, Shuangshuang ^a   Li, Caihong ^a   Zhang, Yang ^a   Yang, Jie ^a   Zheng, Junnian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

factor VII; lidamycin; liver cancer; tissue factor

Indexed keywords

ANTINEOPLASTIC AGENT; FUSION PROTEIN HUMAN FACTOR 7 LIGHT CHAIN LIDAMYCIN; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL DEATH; CHROMATIN CONDENSATION; DNA CLEAVAGE; DRUG CONJUGATION; DRUG EFFICACY; HUMAN; HUMAN CELL; IC 50; LIVER CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINOGLYCOSIDES; ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; ENEDIYNES; FACTOR VII; FEMALE; HEP G2 CELLS; HUMANS; IN SITU NICK-END LABELING; LIVER NEOPLASMS; MICE; MICE, NUDE; THROMBOPLASTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864028073     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1209     Document Type: Article

References (42)

1. Geney R, Chen J, Ojima I. Recent advances in the new generation taxane anticancer agents. Med Chem 2005;1:125.
2. Yamanaka T, Okamoto T, Ichinose Y, et al. Methodological aspects of current problems in target-based anticancer drug development. Int J Clin Oncol 2006;11:167.
3. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750.
4. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992; 70:1194.
5. Contrino J, Hair G, Kreutzer DL, et al. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209.
6. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci U S A 2001;98:12180.
7. Hu Z, Garen A. Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci U S A 2000;97:9221.
8. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci U S A 1999;96:8161.
9. Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152:399.
10. Andoh K, Kubota T, Takada M, et al. Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation. Cancer 1987;59:748.
11. Bauer KA, Conway EM, Bach R, et al. Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res 1989;56:425.
12. Hair GA, Padula S, Zeff R, et al. Tissue factor expression in human leukemic cells. Leuk Res 1996;20:1.
13. Rak J, Milsom C, Magnus N, et al. Tissue factor in tumour progression. Best Pract Res Clin Haematol 2009;22:71.
14. Hu Z, Rao B, Chen S, et al. Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer. Breast Cancer Res Treat 2011;126:589.
15. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134:1087.
16. Wilcox JN, Smith KM, Schwartz SM, et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 1989;86:2839.
17. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983.
18. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1.
19. Ruf W, Kalnik MW, Lund-Hansen T, et al. Characterization of factor VII association with tissue factor in solution. High and low affinity calcium binding sites in factor VII contribute to functionally distinct interactions. J Biol Chem 1991; 266:15719.
20. Toomey JR, Smith KJ, Stafford DW. Localization of the human tissue factor recognition determinant of human factor VIIa. J Biol Chem 1991;266:19198.
21. Tang Y, Borgstrom P, Maynard J, et al. Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther 2007;14:346.
22. Hu Z, Rao B, Chen S, et al. Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VIItargeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. BMC Cancer 2010;10:235.
23. Shoji M, Sun A, Kisiel W, et al. Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Target 2008;16:185.
24. Hu JL, Xue YC, Xie MY, et al. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo) 1988;41:1575.
25. Otani T, Minami Y, Marunaka T, et al. A new macromolecular antitumor antibiotic, C-1027. II. Isolation and physico- chemical properties. J Antibiot (Tokyo) 1988;41:1580.
26. Zhen YS, Ming XY, Yu B, et al. A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity. J Antibiot (Tokyo) 1989;42:1294.
27. Xu YJ, Li DD, Zhen YS. Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells. Cancer Chemother Pharmacol 1990;27:41.
28. Shao RG, Zhen YS. Enediyne anticancer antibiotic lidamycin: Chemistry, biology and pharmacology. Anticancer Agents Med Chem 2008;8:123.
29. Xu YJ, Zhen YS, Goldberg IH. C1027 chromophore, a potent new enediyne antitumor antibiotic, induces sequence-specific double-strand DNA cleavage. Biochemistry 1994;33:5947.
30. McHugh MM, Gawron LS, Matsui S, et al. The antitumor enediyne C-1027 alters cell cycle progression and induces chromosomal aberrations and telomere dysfunction. Cancer Res 2005;65:5344.
31. Jiang B, Li DD, Zhen YS. Induction of apoptosis by enediyne antitumor antibiotic C1027 in HL-60 human promyelocytic leukemia cells. Biochem Biophys Res Commun 1995;208:238.
32. Tanaka T, Fukuda-Ishisaka S, Hirama M, et al. Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore. J Mol Biol 2001;309:267.
33. Xin C, Ye S, Ming Y, et al. Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: Anti-CD20Fab-LDM. Gene Ther 2010;17:1234.
34. Hagen FS, Gray CL, O'Hara P, et al. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci U S A 1986;83:2412.
35. Miao QF, Liu XY, Shang BY, et al. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity. Anticancer Drugs 2007;18:127.
36. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4:381.
37. Zhong G, Zhang S, Li Y, et al. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice. Cancer Lett 2010;295:124.
38. Guo Xf, Zhu Xf, Shang Y, et al. A bispecific enediyneenergized fusion protein containing ligand-based and antibody- based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity. Clin Cancer Res 2010; 16:2085.
39. Williams JI, Weitman S, Gonzalez CM, et al. Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin Cancer Res 2001; 7:724.
40. Weitman S, Marty J, Jolivet J, et al. The new dioxolane, (-)-2-deoxy-3-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res 2000;6:1574.
41. Collier ME, Li C, Ettelaie C. Influence of exogenous tissue factor on estrogen receptor alpha expression in breast cancer cells: Involvement of beta1-integrin, PAR2, and mitogenactivated protein kinase activation. Mol Cancer Res 2008; 6:1807.
42. Wang Z. Non-caspase-mediated apoptosis contributes to the potent cytotoxicity of the enediyne antibiotic lidamycin toward human tumor cells. Biochem Pharmacol 2003; 65:1767.